<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250402021624&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250402021624&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 02 Apr 2025 06:16:25 +0000</lastbuilddate>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00295-8. doi: 10.1016/j.cell.2025.03.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and severity of aGVHD, as well as improved survival. We observed time-of-day variations in the levels of cytokines, especially IL-1α, which controls donor T cell responses after transplantation. The levels of IL-1α in patients were strongly associated with the development of aGVHD. Furthermore, preclinical results showed that the administration of IL-1α neutralizing antibodies markedly alleviated aGVHD and increased survival. Our study suggests that scheduling stem cell infusions early in the day could be a simple yet transformative intervention for preventing aGVHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40168995</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.022>10.1016/j.cell.2025.03.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168995</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yiwen Hou</dc:creator>
<dc:creator>Yue Wu</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>Xiaoxia Hu</dc:creator>
<dc:creator>Yuqian Sun</dc:creator>
<dc:creator>Hongmei Wang</dc:creator>
<dc:creator>Liang Wang</dc:creator>
<dc:creator>Jialin Zhou</dc:creator>
<dc:creator>Zhonglin Zhang</dc:creator>
<dc:creator>Zhiwei Liu</dc:creator>
<dc:creator>Baolin Tang</dc:creator>
<dc:creator>Kaidi Song</dc:creator>
<dc:creator>Guangyu Sun</dc:creator>
<dc:creator>Wen Gao</dc:creator>
<dc:creator>Tianqi Zheng</dc:creator>
<dc:creator>Ping Wu</dc:creator>
<dc:creator>Weiwei Wu</dc:creator>
<dc:creator>Dapeng Ju</dc:creator>
<dc:creator>Xiaoyu Zhu</dc:creator>
<dc:creator>Cheng Zhan</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</dc:title>
<dc:identifier>pmid:40168995</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.022</dc:identifier>
</item>
<item>
<title>Global analysis of protein turnover dynamics in single cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 26:S0092-8674(25)00275-2. doi: 10.1016/j.cell.2025.03.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We performed a large-scale time-series SC-pSILAC analysis of undirected differentiation of human induced pluripotent stem cells (iPSCs) encompassing 6 sampling times over 2 months and analyzed >;1,000 cells. Protein turnover dynamics highlighted differentiation-specific co-regulation of protein complexes with core histone turnover, discriminating dividing and non-dividing cells. Lastly, correlating cell diameter with the abundance of individual proteins showed that histones and some cell-cycle proteins do not scale with cell size. The SC-pSILAC method provides a multidimensional view of protein dynamics in single-cell biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40168994</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.002>10.1016/j.cell.2025.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168994</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pierre Sabatier</dc:creator>
<dc:creator>Maico Lechner</dc:creator>
<dc:creator>Ulises H Guzmán</dc:creator>
<dc:creator>Christian M Beusch</dc:creator>
<dc:creator>Xinlei Zeng</dc:creator>
<dc:creator>Longteng Wang</dc:creator>
<dc:creator>Fabiana Izaguirre</dc:creator>
<dc:creator>Anjali Seth</dc:creator>
<dc:creator>Olga Gritsenko</dc:creator>
<dc:creator>Sergey Rodin</dc:creator>
<dc:creator>Karl-Henrik Grinnemo</dc:creator>
<dc:creator>Zilu Ye</dc:creator>
<dc:creator>Jesper V Olsen</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global analysis of protein turnover dynamics in single cells</dc:title>
<dc:identifier>pmid:40168994</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.002</dc:identifier>
</item>
<item>
<title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00259-4. doi: 10.1016/j.cell.2025.02.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7 blocks this capture site by DNA mimicry, thereby preventing DNA loading and inactivating MukBEF. We propose a comprehensive and unidirectional loading mechanism in which DNA is first captured at the complex's periphery and then ingested through the DNA entry gate, powered by a single cycle of ATP hydrolysis. These findings illuminate a fundamental aspect of how ubiquitous DNA organizers are primed for genome maintenance and demonstrate how this process can be disrupted by viruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40168993</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.032>10.1016/j.cell.2025.02.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168993</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Frank Bürmann</dc:creator>
<dc:creator>Bryony Clifton</dc:creator>
<dc:creator>Sophie Koekemoer</dc:creator>
<dc:creator>Oliver J Wilkinson</dc:creator>
<dc:creator>Dari Kimanius</dc:creator>
<dc:creator>Mark S Dillingham</dc:creator>
<dc:creator>Jan Löwe</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</dc:title>
<dc:identifier>pmid:40168993</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.032</dc:identifier>
</item>
<item>
<title>Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05339-2. doi: 10.1016/j.jacc.2025.03.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Angiopoietin-like 3 (ANGPTL-3) inhibits the activity of lipoprotein lipase and endothelial lipase, increasing both serum low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. SHR-1918 is a fully human monoclonal antibody against ANGPTL-3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to assess the lipid-altering efficacy and safety of SHR-1918 in patients at moderate or higher risk of atherosclerotic cardiovascular disease (ASCVD) with suboptimally controlled hyperlipidemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase 2 study was designed to evaluate the effects of SHR-1918 in hypercholesterolemic patients, who did not achieve optimal LDL-C after 4 to 8 weeks of standard lipid-lowering therapies. A total of 333 patients were enrolled sequentially into 1 of 8 dose cohorts at a 4:1 (active/placebo) ratio. Patients received subcutaneous SHR-1918 at doses of 150, 300, or 600 mg every 4 weeks (Q4W), or SHR-1918 at a dose of 600 mg every 8 weeks (Q8W), alternating with placebo for a total treatment period of 16 weeks. The extension treatment included subcutaneous SHR-1918 at a dose of 150, 300, or 600 mg Q4W over 36 weeks, or SHR-1918 a dose of 600 mg Q8W over 40 weeks and then followed for safety. Prespecified endpoints included percentage change from baseline in LDL-C and TG. Safety was assessed with laboratory test results and by the incidence and severity of adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SHR-1918 demonstrated a clear dose-response relationship with respect to percentage LDL-C lowering for both Q4W and Q8W administration: 21.7%, 27.3%, and 29.9% with 150, 300, and 600 mg Q4W compared with placebo, respectively, and 22.5% with 600 mg Q8W compared with placebo. SHR-1918 also substantially reduced TG, non-high-density lipoprotein cholesterol, apolipoprotein B, and apolipoprotein A1, with a better achievement of LDL-C targets. SHR-1918 was generally well-tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40167414</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.008>10.1016/j.jacc.2025.03.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167414</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaojie Xie</dc:creator>
<dc:creator>Xiaoxia Shi</dc:creator>
<dc:creator>Yuming Zhang</dc:creator>
<dc:creator>Shuhong Su</dc:creator>
<dc:creator>Chenyan Jiang</dc:creator>
<dc:creator>Liu Miao</dc:creator>
<dc:creator>Junkui Wang</dc:creator>
<dc:creator>Daoquan Peng</dc:creator>
<dc:creator>Lingchun Lv</dc:creator>
<dc:creator>Xiaohong Chai</dc:creator>
<dc:creator>Suxin Luo</dc:creator>
<dc:creator>Yang Zheng</dc:creator>
<dc:creator>Shan Huang</dc:creator>
<dc:creator>Dan Zhu</dc:creator>
<dc:creator>Shangshang Liao</dc:creator>
<dc:creator>Meng Ren</dc:creator>
<dc:creator>Xiaohong Gao</dc:creator>
<dc:creator>Haibo Yang</dc:creator>
<dc:creator>Hao Zhou</dc:creator>
<dc:creator>Yuquan He</dc:creator>
<dc:creator>Yajun Han</dc:creator>
<dc:creator>Jiahong Xu</dc:creator>
<dc:creator>Lin Zhang</dc:creator>
<dc:creator>Laijing Du</dc:creator>
<dc:creator>Zhuhua Yao</dc:creator>
<dc:creator>Jianlong Sheng</dc:creator>
<dc:creator>Xiaoping Peng</dc:creator>
<dc:creator>Xiaowen Chen</dc:creator>
<dc:creator>Juxiang Li</dc:creator>
<dc:creator>Jie Mi</dc:creator>
<dc:creator>Qiang Lu</dc:creator>
<dc:creator>Hongju Wang</dc:creator>
<dc:creator>Zheng Shen</dc:creator>
<dc:creator>Zhilin Zhao</dc:creator>
<dc:creator>Feng Gao</dc:creator>
<dc:creator>Chao Lv</dc:creator>
<dc:creator>Min Zhu</dc:creator>
<dc:creator>Ying Zhu</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study</dc:title>
<dc:identifier>pmid:40167414</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.008</dc:identifier>
</item>
<item>
<title>An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment. (A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia [PURSUIT]; NCT06173570).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 27:S0735-1097(25)05907-8. doi: 10.1016/j.jacc.2025.03.499. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Most patients at high-risk for cardiovascular events do not achieve lipid goals advocated by American College of Cardiology/American Heart Association (ACC/AHA) guidelines despite the wide availability of lipid-lowering therapy. AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The phase 2 randomized, double-blind, placebo-controlled, multicenter PURSUIT trial evaluated the efficacy and safety of AZD0780 in patients with hypercholesterolemia already on background moderate-to-high-intensity statin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Eligible study patients had a fasting low-density lipoprotein cholesterol (LDL-C) level of ≥70 mg/dL (1.8 mmol/L) and &lt;190 mg/dL (4.9 mmol/L), and triglycerides &lt;400 mg/dL on stable dose of moderate- or high-intensity statins, as defined by ACC/AHA or local guidelines, with or without ezetimibe at baseline. The study randomized patients 1:1:1:1:1 to receive AZD0780 1, 3, 10, or 30 mg, or matching placebo, oral once daily, for 12 weeks. The primary efficacy endpoint was percent change of LDL-C from baseline to week 12. Safety and tolerability evaluations included the number of adverse events, vital signs, electrocardiograms, and laboratory assessments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, the study randomized 428 patients, of whom 426 started treatment. Patients were 52.1% male, with an average age of 62.4 ± 7.6 years. At week 12, compared with baseline, the placebo-corrected difference in least squares mean percent change of LDL-C for AZD0780 1, 3, 10, and 30 mg vs placebo was -35.3% (95% CI: -43.6% to -26.9%), -37.9% (95% CI:-46.3% to -29.5%), -45.2% (95% CI: -53.5% to -36.9%), and -50.7% (95% CI: -59.0% to -42.4%), respectively. Baseline statin use, moderate vs high intensity, did not alter AZD0780 efficacy. The proportion of patients reaching the ACC/AHA guideline LDL-C goal for high-risk patients increased in a dose-proportional manner. Adverse events compared similarly between the total AZD0780 treatment group (38.2%) and placebo (32.6%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment. (A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia [PURSUIT]; NCT06173570).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40167413</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.499>10.1016/j.jacc.2025.03.499</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167413</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael J Koren</dc:creator>
<dc:creator>Rick B Vega</dc:creator>
<dc:creator>Nikhil Agrawal</dc:creator>
<dc:creator>Yuejia Xu</dc:creator>
<dc:creator>April M Barbour</dc:creator>
<dc:creator>Hongtao Yu</dc:creator>
<dc:creator>Emelie Wallerstedt</dc:creator>
<dc:creator>Debra Carter</dc:creator>
<dc:creator>Jessica Middlemiss</dc:creator>
<dc:creator>Lee Twaddle</dc:creator>
<dc:creator>Michael C McCarthy</dc:creator>
<dc:creator>Jaya B Rosenmeier</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial</dc:title>
<dc:identifier>pmid:40167413</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.499</dc:identifier>
</item>
<item>
<title>Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05927-3. doi: 10.1016/j.jacc.2025.03.502. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40167412</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.502>10.1016/j.jacc.2025.03.502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167412</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dirk J Blom</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk</dc:title>
<dc:identifier>pmid:40167412</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.502</dc:identifier>
</item>
<item>
<title>Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40167249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy European men and women was predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 1:ehaf209. doi: 10.1093/eurheartj/ehaf209. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Recent data from a large American cohort of women strongly support universal one-time screening for LDL cholesterol, high-sensitivity C-reactive protein (hsCRP), and lipoprotein(a) [Lp(a)] in primary prevention. This study addresses the validity and generalizability of this novel primary prevention strategy in a large prospective European cohort of initially healthy men and women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Plasma levels of LDL cholesterol, hsCRP, and Lp(a) were measured at study entry in 17 087 participants from the EPIC-Norfolk study who were subsequently followed over a period of 20 years for major adverse cardiovascular events (MACEs). Competing risk- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident MACE across quintiles of each biomarker and sought evidence of independent as well as additive effects over time were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 20-year follow-up, a total of 3249 MACEs occurred. Increasing quintiles of baseline LDL cholesterol, hsCRP, and Lp(a) all predicted 20-year risks; the multivariable-adjusted HRs in a comparison of the top to bottom quintile were 1.78 (95% CI: 1.57-2.00) for LDL cholesterol, 1.55 (95% CI: 1.37-1.74) for hsCRP, and 1.19 (95% CI: 1.07-1.33) for Lp(a). Compared with individuals with no biomarker elevations, the multivariable-adjusted HRs for incident MACE were 1.33, 1.68, and 2.41 for those with one, two, or three biomarkers in the top quintile, respectively (all P &lt; .001). Each biomarker demonstrated independent contributions to overall risk and findings were consistent in analyses stratified by sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy European men and women was predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40167249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40167249</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf209>10.1093/eurheartj/ehaf209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40167249</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jordan M Kraaijenhof</dc:creator>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Ask T Nordestgaard</dc:creator>
<dc:creator>Laurens F Reeskamp</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>S Matthijs Boekholdt</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study</dc:title>
<dc:identifier>pmid:40167249</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf209</dc:identifier>
</item>
<item>
<title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 1;46(13):1173-1177. doi: 10.1093/eurheartj/ehaf138.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40166867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf138>10.1093/eurheartj/ehaf138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166867</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</dc:title>
<dc:identifier>pmid:40166867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf138</dc:identifier>
</item>
<item>
<title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.071741. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined cardiac lymphatic alterations in mice with HFpEF with comorbid obesity and hypertension, and in heart tissues from patients with HFpEF. Using genetically engineered mouse models and various cellular and molecular techniques, we investigated the role of cardiac lymphatics in HFpEF and the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In mice with HFpEF, cardiac lymphatics displayed substantial structural and functional anomalies, including decreased lymphatic endothelial cell (LEC) density, vessel fragmentation, reduced branch connections, and impaired capacity to drain fluids and immune cells. LEC numbers and marker expression levels were also decreased in heart tissues from patients with HFpEF. Stimulating lymphangiogenesis with an adeno-associated virus expressing an engineered variant of vascular endothelial growth factor C (VEGFC<sup>C156S</sup>) that selectively activates vascular endothelial growth factor receptor 3 (VEGFR3) in LECs restored cardiac lymphatic integrity and substantially alleviated HFpEF. Through discovery-driven approaches, defective branched-chain amino acid (BCAA) catabolism was identified as a predominant metabolic signature in HFpEF cardiac LECs. Overexpression of branched-chain ketoacid dehydrogenase kinase (encoded by the <i>Bckdk</i> gene), which inactivates branched-chain ketoacid dehydrogenase (the rate-limiting enzyme in BCAA catabolism), resulted in spontaneous lymphangiogenic defects in LECs. In mice, inducible <i>Bckdk</i> gene deletion in LECs to enhance their BCAA catabolism preserved cardiac lymphatic integrity and protected against HFpEF. BCAA catabolic defects caused ligand-independent phosphorylation of VEGFR3 in the cytoplasm by Src kinase, leading to lysosomal degradation of VEGFR3 instead of its trafficking to the cell membrane. Reduced VEGFR3 availability on the cell surface impeded downstream Akt (protein kinase B) activation, hindered glucose uptake and utilization, and inhibited lymphangiogenesis in LECs with BCAA catabolic defects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40166847</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071741>10.1161/CIRCULATIONAHA.124.071741</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166847</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiong Guo</dc:creator>
<dc:creator>Chong Huang</dc:creator>
<dc:creator>Ling Zhang</dc:creator>
<dc:creator>Guangyu Hu</dc:creator>
<dc:creator>Yunhui Du</dc:creator>
<dc:creator>Xiyao Chen</dc:creator>
<dc:creator>Fangfang Sun</dc:creator>
<dc:creator>Tongzheng Li</dc:creator>
<dc:creator>Zhe Cui</dc:creator>
<dc:creator>Congye Li</dc:creator>
<dc:creator>Yongzhen Guo</dc:creator>
<dc:creator>Wenjun Yan</dc:creator>
<dc:creator>Yunlong Xia</dc:creator>
<dc:creator>Shan Wang</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Zhen Lin</dc:creator>
<dc:creator>Xinyi Wang</dc:creator>
<dc:creator>Zhengyang Wang</dc:creator>
<dc:creator>Fuyang Zhang</dc:creator>
<dc:creator>Ling Tao</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</dc:title>
<dc:identifier>pmid:40166847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071741</dc:identifier>
</item>
<item>
<title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group (<i>P</i>=0.42). The mortality rate was 13% in both groups, with no difference in survival probability (<i>P</i>=0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7; <i>P</i>=0.69]). Major complications occurred in 1% of thoracenteses performed during the study period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05017753.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40166829</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073521>10.1161/CIRCULATIONAHA.124.073521</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166829</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Signe Glargaard</dc:creator>
<dc:creator>Jakob Hartvig Thomsen</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Matias Greve Lindholm</dc:creator>
<dc:creator>Christian Axel Bang</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Rasmus Vedby Rasmussen</dc:creator>
<dc:creator>Brian Bridal Løgstrup</dc:creator>
<dc:creator>Søren Vraa</dc:creator>
<dc:creator>Nis Stride</dc:creator>
<dc:creator>Ekim Seven</dc:creator>
<dc:creator>Anders Barasa</dc:creator>
<dc:creator>Marlene Tofterup</dc:creator>
<dc:creator>Dan Eik Høfsten</dc:creator>
<dc:creator>Kasper Rossing</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</dc:title>
<dc:identifier>pmid:40166829</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073521</dc:identifier>
</item>
<item>
<title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.121.058621. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The National Institutes of Health Library of Integrated Network-Based Cellular Signatures database was interrogated to identify US Food and Drug Administration-approved compounds that demonstrated the ability to reverse the transcriptional effects of <i>LMNA</i> knockdown. Top hits from this screening were validated in vitro with patient-specific induced pluripotent stem cell-derived cardiomyocytes combined with force measurement, gene expression profiling, electrophysiology, and protein expression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Several angiotensin receptor blockers were identified from our in silico screen. Of these, olmesartan significantly elevated the expression of sarcomeric genes and rate and force of contraction and ameliorated arrhythmogenic potential. In addition, olmesartan exhibited the ability to reduce phosphorylation of extracellular signal-regulated kinase 1 in <i>LMNA</i>-mutant induced pluripotent stem cell-derived cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40166828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.121.058621>10.1161/CIRCULATIONAHA.121.058621</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166828</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Kort</dc:creator>
<dc:creator>Nazish Sayed</dc:creator>
<dc:creator>Chun Liu</dc:creator>
<dc:creator>Gema Mondéjar-Parreño</dc:creator>
<dc:creator>Jens Forsberg</dc:creator>
<dc:creator>Emily Eugster</dc:creator>
<dc:creator>Sean M Wu</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>Stefan Jovinge</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</dc:title>
<dc:identifier>pmid:40166828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.121.058621</dc:identifier>
</item>
<item>
<title>Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40164778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor role in haemostasis but contributes substantially to thrombus expansion, making it an attractive target to mitigate bleeding while maintaining antithrombotic efficacy. Various novel inhibitors, including antisense oligonucleotides, monoclonal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 31. doi: 10.1038/s41569-025-01144-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor role in haemostasis but contributes substantially to thrombus expansion, making it an attractive target to mitigate bleeding while maintaining antithrombotic efficacy. Various novel inhibitors, including antisense oligonucleotides, monoclonal antibodies and small molecules, have been developed. Phase II trials in orthopaedic surgery showed dose-dependent reductions in venous thromboembolism without significantly increasing bleeding compared with enoxaparin. In the first phase III trial of a small-molecule inhibitor of activated factor XI in patients with atrial fibrillation, asundexian was associated with a reduction in bleeding but also a higher risk of stroke, compared with apixaban. Factor XI inhibitors appear safe and hold promise for secondary prevention in myocardial infarction and ischaemic stroke, with ongoing phase III trials assessing their broader efficacy and safety. This Review discusses the rationale, pharmacology, evidence and future directions of factor XI inhibitors across various clinical settings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40164778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40164778</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01144-z>10.1038/s41569-025-01144-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40164778</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Vijay Kunadian</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism</dc:title>
<dc:identifier>pmid:40164778</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01144-z</dc:identifier>
</item>
<item>
<title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.125.074425. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance (CS) with delayed TAVR in patients with asymptomatic, severe aortic stenosis (AS). Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A core laboratory measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT). Associations between biomarker levels and risk of the trial primary endpoint (death, stroke, or unplanned cardiovascular hospitalization) and other secondary endpoints were examined with Kaplan-Meier curves and Cox proportional hazard models. Interaction tests were performed to assess whether the treatment effect of early TAVR, compared with CS, differed according to biomarker levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 901 patients randomized in EARLY TAVR, 798 (89%) had biospecimens measured (median NT-proBNP 287 [145, 601]; median hs-cTnT 14.6 [10.5, 21.0]). Higher levels of NT-proBNP and hs-cTnT were broadly associated with higher event rates for multiple endpoints. In general, there was no significant interaction between baseline biomarkers and treatment group with respect to any composite or individual endpoint examined, although trends broadly demonstrated a greater relative benefit of early TAVR at lower biomarker levels. There was a significant interaction between hs-cTnT and treatment group with respect to death or heart failure hospitalization (HFH) (interaction p=0.04) and HFH alone (interaction p=0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. For some endpoints, higher baseline NT-proBNP was associated with numerically greater absolute risk reduction with early TAVR than lower NT-proBNP levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in asymptomatic patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163596</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074425>10.1161/CIRCULATIONAHA.125.074425</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163596</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>J Bradley Oldemeyer</dc:creator>
<dc:creator>Yan Ru Su</dc:creator>
<dc:creator>Kashish Goel</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Vasilis Babaliaros</dc:creator>
<dc:creator>David Daniels</dc:creator>
<dc:creator>Adnan Chhatriwalla</dc:creator>
<dc:creator>Hussam S Suradi</dc:creator>
<dc:creator>Pinak Shah</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Thom Dahle</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Tej Sheth</dc:creator>
<dc:creator>Jeremiah Depta</dc:creator>
<dc:creator>James T DeVries</dc:creator>
<dc:creator>Jeffrey Southard</dc:creator>
<dc:creator>Andrei Pop</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Yanglu Zhao</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>EARLY TAVR Trial Executive Committee and Study Investigators</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</dc:title>
<dc:identifier>pmid:40163596</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074425</dc:identifier>
</item>
<item>
<title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e865. doi: 10.1161/CIR.0000000000001328. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163565</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001328>10.1161/CIR.0000000000001328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163565</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Tanveer Rab</dc:creator>
<dc:creator>Jaqueline E Tamis-Holland</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Heather Baker</dc:creator>
<dc:creator>Mauricio G Cohen</dc:creator>
<dc:creator>Mercedes Cruz-Ruiz</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Tracy A DeWald</dc:creator>
<dc:creator>Islam Y Elgendy</dc:creator>
<dc:creator>Dmitriy N Feldman</dc:creator>
<dc:creator>Abhinav Goyal</dc:creator>
<dc:creator>Ijeoma Isiadinso</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Debabrata Mukherjee</dc:creator>
<dc:creator>Elke Platz</dc:creator>
<dc:creator>Susan B Promes</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Rachel Schunder</dc:creator>
<dc:creator>Binita Shah</dc:creator>
<dc:creator>Jason P Stopyra</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Marlene S Williams</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:40163565</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001328</dc:identifier>
</item>
<item>
<title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):910-912. doi: 10.1161/CIRCULATIONAHA.125.073544. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163564</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073544>10.1161/CIRCULATIONAHA.125.073544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163564</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Terrence M Yau</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</dc:title>
<dc:identifier>pmid:40163564</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073544</dc:identifier>
</item>
<item>
<title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e866. doi: 10.1161/CIR.0000000000001325. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163563</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001325>10.1161/CIR.0000000000001325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163563</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nian Cao</dc:creator>
<dc:creator>Cong Lan</dc:creator>
<dc:creator>Caiyu Chen</dc:creator>
<dc:creator>Zaicheng Xu</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Shuo Zheng</dc:creator>
<dc:creator>Xue Gong</dc:creator>
<dc:creator>Hongmei Ren</dc:creator>
<dc:creator>Zhuxin Li</dc:creator>
<dc:creator>Shuang Qu</dc:creator>
<dc:creator>Cheng Yu</dc:creator>
<dc:creator>Jining Yang</dc:creator>
<dc:creator>Pedro A Jose</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Gengze Wu</dc:creator>
<dc:creator>Cuimei Hu</dc:creator>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</dc:title>
<dc:identifier>pmid:40163563</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001325</dc:identifier>
</item>
<item>
<title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e864. doi: 10.1161/CIR.0000000000001326. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163562</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001326>10.1161/CIR.0000000000001326</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163562</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and American College of Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title>
<dc:identifier>pmid:40163562</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001326</dc:identifier>
</item>
<item>
<title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e863. doi: 10.1161/CIR.0000000000001324. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163561</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001324>10.1161/CIR.0000000000001324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163561</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pei-Ni Jone</dc:creator>
<dc:creator>Adriana Tremoulet</dc:creator>
<dc:creator>Nadine Choueiter</dc:creator>
<dc:creator>Samuel R Dominguez</dc:creator>
<dc:creator>Ashraf S Harahsheh</dc:creator>
<dc:creator>Yoshihide Mitani</dc:creator>
<dc:creator>Meghan Zimmerman</dc:creator>
<dc:creator>Ming-Tai Lin</dc:creator>
<dc:creator>Kevin G Friedman</dc:creator>
<dc:creator>American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40163561</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001324</dc:identifier>
</item>
<item>
<title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e769-e770. doi: 10.1161/CIRCULATIONAHA.124.073362. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163560</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073362>10.1161/CIRCULATIONAHA.124.073362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163560</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Miao Yu</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073362</dc:identifier>
</item>
<item>
<title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):893-895. doi: 10.1161/CIRCULATIONAHA.124.072830. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072830>10.1161/CIRCULATIONAHA.124.072830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163559</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</dc:title>
<dc:identifier>pmid:40163559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072830</dc:identifier>
</item>
<item>
<title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402021624&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e767-e768. doi: 10.1161/CIRCULATIONAHA.124.072950. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402021624&v=2.18.0.post9+e462414">40163558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072950>10.1161/CIRCULATIONAHA.124.072950</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163558</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072950</dc:identifier>
</item>





























</channel>
</rss>